Do analysts recommend TRIB or PETV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TRIB or PETV more profitable?

Trinity Biotech has a net margin of -70.06% compared to PetVivo's net margin of -902.82%. Trinity Biotech's return on equity of 0.00% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Trinity Biotech -70.06% N/A -32.13% PetVivo -902.82% -4,813.07% -281.78%

Does the media favor TRIB or PETV?

In the previous week, PetVivo had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for PetVivo and 1 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TRIB or BEAT?

HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 828.07%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartBeam 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts rate TRIB or MODD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to TRIB or MODD?

In the previous week, Modular Medical had 2 more articles in the media than Trinity Biotech. MarketBeat recorded 3 mentions for Modular Medical and 1 mentions for Trinity Biotech. Modular Medical's average media sentiment score of 0.11 beat Trinity Biotech's score of 0.00 indicating that Modular Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Modular Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FEMY or TRIB?

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 1,720.83%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FEMY or TRIB more profitable?

Trinity Biotech has a net margin of -70.06% compared to Femasys' net margin of -534.36%. Trinity Biotech's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% Trinity Biotech -70.06% N/A -32.13%

Does the media prefer FEMY or TRIB?

In the previous week, Femasys had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for Femasys and 1 mentions for Trinity Biotech. Femasys' average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RVP or TRIB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer RVP or TRIB?

In the previous week, Retractable Technologies had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for Retractable Technologies and 1 mentions for Trinity Biotech. Retractable Technologies' average media sentiment score of 0.36 beat Trinity Biotech's score of 0.00 indicating that Retractable Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Retractable Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trinity Biotech (TRIB) Competitors

$8.13 -0.93 (-10.24%)

As of 02:47 PM Eastern

Compare

TRIB vs. PETV, BEAT, MODD, FEMY, and RVP

Should you buy Trinity Biotech stock or one of its competitors? Trinity Biotech's main competitors and comparable companies include PetVivo (PETV), HeartBeam (BEAT), Modular Medical (MODD), Femasys (FEMY), and Retractable Technologies (RVP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Trinity Biotech compare to PetVivo?

Trinity Biotech (NASDAQ:TRIB) and PetVivo (NASDAQ:PETV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Trinity Biotech has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PetVivo had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for PetVivo and 1 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trinity Biotech has a net margin of -70.06% compared to PetVivo's net margin of -902.82%. Trinity Biotech's return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
PetVivo	-902.82%	-4,813.07%	-281.78%

PetVivo has lower revenue, but higher earnings than Trinity Biotech. PetVivo is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.15	-$37.38M	-$44.26	N/A
PetVivo	$1.05M	22.86	-$10.95M	-$0.34	N/A

Summary

Trinity Biotech beats PetVivo on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to HeartBeam?

Trinity Biotech (NASDAQ:TRIB) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

HeartBeam has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
HeartBeam	N/A	-686.78%	-348.65%

Trinity Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, indicating that its stock price is 180% less volatile than the broader market.

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Trinity Biotech had 1 more articles in the media than HeartBeam. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for HeartBeam. Trinity Biotech's average media sentiment score of 0.00 equaled HeartBeam'saverage media sentiment score.

Company	Overall Sentiment
Trinity Biotech	Neutral
HeartBeam	Neutral

HeartBeam has a consensus target price of $4.00, suggesting a potential upside of 828.07%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

HeartBeam has lower revenue, but higher earnings than Trinity Biotech. HeartBeam is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.15	-$37.38M	-$44.26	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

Summary

HeartBeam beats Trinity Biotech on 8 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to Modular Medical?

Trinity Biotech (NASDAQ:TRIB) and Modular Medical (NASDAQ:MODD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 7.1% of Modular Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Modular Medical had 2 more articles in the media than Trinity Biotech. MarketBeat recorded 3 mentions for Modular Medical and 1 mentions for Trinity Biotech. Modular Medical's average media sentiment score of 0.11 beat Trinity Biotech's score of 0.00 indicating that Modular Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Modular Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trinity Biotech has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Modular Medical has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Modular Medical has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Modular Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Modular Medical	N/A	-292.14%	-222.79%

Modular Medical has lower revenue, but higher earnings than Trinity Biotech. Modular Medical is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.15	-$37.38M	-$44.26	N/A
Modular Medical	N/A	N/A	-$28.24M	-$8.69	N/A

Summary

Trinity Biotech beats Modular Medical on 7 of the 12 factors compared between the two stocks.

How does Trinity Biotech compare to Femasys?

Femasys (NASDAQ:FEMY) and Trinity Biotech (NASDAQ:TRIB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Trinity Biotech has a net margin of -70.06% compared to Femasys' net margin of -534.36%. Trinity Biotech's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Trinity Biotech	-70.06%	N/A	-32.13%

Femasys has a beta of -2.07, indicating that its stock price is 307% less volatile than the broader market. Comparatively, Trinity Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

65.3% of Femasys shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 7.8% of Femasys shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 1,720.83%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Femasys has higher earnings, but lower revenue than Trinity Biotech. Femasys is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.30M	10.00	-$18.63M	-$3.53	N/A
Trinity Biotech	$43.79M	0.15	-$37.38M	-$44.26	N/A

In the previous week, Femasys had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for Femasys and 1 mentions for Trinity Biotech. Femasys' average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trinity Biotech beats Femasys on 8 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Trinity Biotech (NASDAQ:TRIB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Retractable Technologies has a net margin of -41.11% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
Trinity Biotech	-70.06%	N/A	-32.13%

Retractable Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Trinity Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Retractable Technologies has higher earnings, but lower revenue than Trinity Biotech. Retractable Technologies is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$33.90M	0.63	-$7.01M	-$0.12	N/A
Trinity Biotech	$43.79M	0.15	-$37.38M	-$44.26	N/A

In the previous week, Retractable Technologies had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for Retractable Technologies and 1 mentions for Trinity Biotech. Retractable Technologies' average media sentiment score of 0.36 beat Trinity Biotech's score of 0.00 indicating that Retractable Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Retractable Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Retractable Technologies beats Trinity Biotech on 9 of the 14 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRIB vs. The Competition

Export

Metric	Trinity Biotech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.79M	$5.47B	$7.16B	$12.78B
Dividend Yield	N/A	1.76%	2.54%	9.15%
P/E Ratio	-0.19	25.05	271.88	25.30
Price / Sales	0.15	88.16	700.01	108.13
Price / Cash	N/A	32.95	77.07	52.39
Price / Book	-0.01	6.32	10.86	6.36
Net Income	-$37.38M	$150.94M	$3.48B	$358.07M
7 Day Performance	-13.06%	-1.84%	-0.82%	-0.05%
1 Month Performance	-32.86%	-0.55%	2.80%	-0.94%
1 Year Performance	-74.71%	8.43%	21.60%	11.95%

Trinity Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRIB Trinity Biotech	0.6012 of 5 stars	$8.13 -10.2%	N/A	-73.0%	$6.70M	$43.79M	N/A	480	News Coverage Gap Up
PETV PetVivo	N/A	$0.68 +0.6%	N/A	-19.9%	$25.81M	$1.05M	N/A	20
BEAT HeartBeam	1.8092 of 5 stars	$0.44 +3.8%	$4.00 +802.9%	-67.5%	$24.96M	N/A	N/A	1,700
MODD Modular Medical	0.2504 of 5 stars	$3.04 -17.3%	N/A	-86.9%	$24.70M	N/A	N/A	20	Gap Up
FEMY Femasys	2.8835 of 5 stars	$2.76 -7.4%	$50.00 +1,711.6%	-65.2%	$23.13M	$2.29M	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Competitors

TRIB vs. PETV, BEAT, MODD, FEMY, and RVP

How does Trinity Biotech compare to PetVivo?

Summary

How does Trinity Biotech compare to HeartBeam?

Summary

How does Trinity Biotech compare to Modular Medical?

Summary

How does Trinity Biotech compare to Femasys?

Summary

How does Trinity Biotech compare to Retractable Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Competitors

TRIB vs. PETV, BEAT, MODD, FEMY, and RVP

How does Trinity Biotech compare to PetVivo?

Do analysts recommend TRIB or PETV?

Which has more risk and volatility, TRIB or PETV?

Do institutionals and insiders believe in TRIB or PETV?

Does the media favor TRIB or PETV?

Is TRIB or PETV more profitable?

Which has stronger earnings and valuation, TRIB or PETV?

Summary

How does Trinity Biotech compare to HeartBeam?

Is TRIB or BEAT more profitable?

Which has more risk & volatility, TRIB or BEAT?

Do insiders and institutionals hold more shares of TRIB or BEAT?

Does the media favor TRIB or BEAT?

Do analysts rate TRIB or BEAT?

Which has higher earnings & valuation, TRIB or BEAT?

Summary

How does Trinity Biotech compare to Modular Medical?

Do insiders and institutionals hold more shares of TRIB or MODD?

Do analysts rate TRIB or MODD?

Does the media refer more to TRIB or MODD?

Which has more risk & volatility, TRIB or MODD?

Is TRIB or MODD more profitable?

Which has better earnings & valuation, TRIB or MODD?

Summary

How does Trinity Biotech compare to Femasys?

Is FEMY or TRIB more profitable?

Which has more risk & volatility, FEMY or TRIB?

Do institutionals and insiders hold more shares of FEMY or TRIB?

Do analysts prefer FEMY or TRIB?

Which has better earnings & valuation, FEMY or TRIB?

Does the media prefer FEMY or TRIB?

Summary

How does Trinity Biotech compare to Retractable Technologies?

Do analysts prefer RVP or TRIB?

Is RVP or TRIB more profitable?

Which has more risk and volatility, RVP or TRIB?

Do institutionals & insiders hold more shares of RVP or TRIB?

Which has higher valuation & earnings, RVP or TRIB?

Does the media prefer RVP or TRIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools